Keywords: |
adult; clinical article; treatment outcome; aged; advanced cancer; drug efficacy; phase 2 clinical trial; mucosa inflammation; vomiting; drug administration schedule; antineoplastic activity; pyrimidines; rash; sarcoma; fibrosarcoma; soft tissue sarcoma; leiomyosarcoma; folic acid antagonists; administration, oral; mouth mucosa; phase ii; soft tissue neoplasms; liposarcoma; bone marrow toxicity; oral drug administration; middle age; drug evaluation; endometrium sarcoma; piritrexim; human; male; female; priority journal; article; support, non-u.s. gov't
|